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A B S T R A C T
Purpose
Little is known about the trajectory of post-traumatic stress disorder (PTSD) symptoms in cancer
survivors, despite the fact that such knowledge can guide treatment. Therefore, this study
examined changes in PTSD symptoms among long-term survivors of non-Hodgkin’s lymphoma
(NHL) and identified demographic, clinical, and psychosocial predictors and correlates of
PTSD symptomatology.
Patients and Methods
Surveys were mailed to 682 NHL survivors who participated in an earlier survey and now were at
least 7 years postdiagnosis. Information was obtained regarding PTSD symptoms, positive and
negative perceptions of the cancer experience (ie, impact of cancer), and other potential correlates
of PTSD.
Results
A total of 566 individuals participated (83% response rate) with a median of 12.9 years since
diagnosis; respondents were 52% female and 87% white. Although half (51%) of the respondents
reported no PTSD symptoms and 12% reported a resolution of symptoms, more than one-third
(37%) reported persistence or worsening of symptoms over 5 years. Survivors who reported a low
income, stage  2 at diagnosis, aggressive lymphoma, having received chemotherapy, and
greater impact of cancer (both positive and negative) at the initial survey had more PTSD
symptoms at follow-up. In multivariable analysis, income and negative impacts of cancer were
independent predictors of PTSD symptoms.
Conclusion
More than one-third of long-term NHL survivors experience persisting or worsening PTSD
symptoms. Providers should be aware of enduring risk; early identification of those at prolonged
risk with standardized measures and treatments that target perceptions of the cancer experience
might improve long-term outcomes.
J Clin Oncol 29:4526-4533. © 2011 by American Society of Clinical Oncology
INTRODUCTION
Recent advances in treating non-Hodgkin’s lym-
phoma (NHL), one of the most common forms of
cancer, have led to a more than doubling of the
5-year relative survival rate from the 1960s, from
31% to 69%.1 Thus, NHL is often perceived by
survivors as a life-long chronic illness, with alter-
nating symptom-free and symptom-exacerbation
phases that may require treatment. As with
other chronic illnesses, comorbidities are com-
mon in the context of NHL, including symp-
toms of post-traumatic stress disorder (PTSD),
which were identified among 39% of NHL survi-
vors2 and have been shown to be associated with
poor quality of life3-5 and depression6 in other
cancer samples.
PTSD symptoms of avoidance, arousal, and
re-experiencing have been identified in individuals
diagnosed with an adult cancer in several cross-
sectional studies.2,7,8 A few longitudinal studies have
examined cancer-related PTSD during the first year
after a diagnosis.9-11 However, none have examined
the trajectory of cancer-related PTSD symptoms in
long-term survivors, so nothing is known regarding
symptom stability in this population. Furthermore,
little is known about the predictors of PTSD in this
understudied group of NHL survivors, the knowl-
edge of which may be helpful in identifying those at
future need.
Our initial study defined the NHL survivor ex-
perience in terms of PTSD,2 quality of life,12 and the
impact of cancer (IOC).13,14 That study was cross
sectional with a median of 8 years postdiagnosis.
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This follow-up assessment resurveyed study participants 5 years later
and extends our examination to a median of 13 years postdiagnosis,
providing a unique window into the longitudinal NHL experience.
The purpose of this follow-up study is to examine change in PTSD
symptoms over a 5-year period among NHL survivors and identify
demographic, clinical, and psychosocial factors associated with
changes in PTSD symptoms. We hypothesized that PTSD symp-
toms would persist or worsen for a small proportion of the sample,
particularly given the potential for disease relapse, and that non-
white race, younger age, less education and social support, comor-
bidities, and negative perceptions of the cancer experience would
be associated with follow-up PTSD symptoms after controlling for
initial PTSD symptoms. These findings have important implica-
tions for clinical care and future research on the late effects of NHL
diagnosis and treatment.
PATIENTS AND METHODS
Study Design and Patient Recruitment
We conducted a longitudinal follow-up assessment of NHL survivors
who consented to an earlier study and were treated at Duke University or the
University of North Carolina Cancer Centers. The institutional review boards
at both institutions approved this study. Initial study eligibility criteria re-
quired that individuals had been diagnosed with NHL  2 years previously
and were  19 years of age; details of initial study procedures are published
elsewhere.2 Hence, the study cohort for this study was  7 years postdiagnosis
and  24 years of age. The consent form used in the initial study included a
statement of willingness to be recontacted within the next 5 years. Follow-up
data were collected in 2010; surveys from 2005 and 2010 were linked at the
individual patient level to facilitate within-person analyses of change over time.
Procedures
In accordance with the Dillman method for administering surveys,15 a
brief prenotice letter was mailed to patients who were assumed living and
within 5 years of their initial study enrollment. The follow-up survey was
mailed 2 weeks later and included a postage-paid return envelope, a $2 incen-
tive, and a form to indicate interest in participating in future studies and/or
receiving an educational CD and summary of research findings. Thank-you
and/or reminder postcards were mailed 2 weeks later, and nonresponders were
sent replacement surveys and later telephoned to confirm receipt of the survey.
Instruments
Data collected in this second survey included demographic and clini-
cal status (eg, change in marital status, recurrence of NHL). The Self-
Administered Comorbidity Questionnaire (SCQ), a 12-item self-report
version of the Charlson Index, was used to assess non–cancer-related prob-
lems.16 In scoring the SCQ, an individual can receive up to 3 points for each of
15 medical conditions (1 point each for presence of the problem, current
treatment, and functional limitation; range, 0 to 45 points).
Psychosocial well-being was assessed with the Medical Outcomes Study
Social Support Survey (MOS-SSS)17 and the Impact of Cancer Version 2
(IOCv2) surveys.13 Scores for the 20-item MOS-SSS range from 20 to 100, with
higher scores representing better social support. The IOCv2 assessed the
positive life changes and negative impacts attributed to the cancer experi-
ence. It includes 37 items to measure four positive (Altruism/Empathy,
Health Awareness, Meaning of Cancer, Positive Self-Evaluation) and four
negative (Appearance Concerns, Body Change Concerns, Life Interfer-
ence, Worry) subscales, which total to Positive and Negative Impact Sum-
mary scores (range, 1 to 5). Higher Positive Impact Summary scores
indicate greater positive perceptions, and higher Negative Impact Sum-
mary scores indicate more negative perceptions.
Post-traumatic stress symptoms were measured with the PTSD
Checklist-Civilian Version (PCL-C),18 a self-report symptom checklist that
closely mirrors the diagnosis criteria in Diagnostic and Statistical Manual of
Mental Disorders, Revision IV (DSM-IV).19 The instructions were modified
so that symptoms were keyed to the particular traumatic stressor of interest;
specifically, participants were asked to rate each PTSD symptom in the past 4
weeks with respect to their NHL diagnosis and treatment. Each of 17 symp-
toms is rated with respect to intensity on a scale of 1 (not at all) to 5 (extremely
bothersome). Two approaches were used to construct an aggregate score in
assessing symptoms: the continuous score (range, 17 to 85) and the symptom
cluster method, which follows the DSM-IV PTSD symptom structure. For
example, individuals would be considered as having a PTSD symptom if they
reported having been at least moderately bothered by (score  3) at least one of
five re-experiencing symptoms (eg, nightmares), at least three of seven avoid-
ance symptoms (eg, evading follow-ups), or at least two of five arousal symp-
toms (eg, easily startled).
Statistical Analyses
To compare follow-up study participants and nonparticipants with
respect to initial demographic, clinical, and psychosocial characteristics
and PTSD, we tested for differences between participants and both dece-
dents and nonresponders by using t tests for continuous measures and 2
tests for categorical measures. Because initial PTSD symptomatology is one
of the strongest predictors of PTSD symptoms at follow-up, all analyses
that examined characteristics associated with follow-up PCL-C scores were
adjusted for the initial score of this measure. To assess the association
between each of the independent variables (ie, data from the initial survey
as predictors and from the follow-up survey as correlates) and the
follow-up PCL-C, we used a series of linear regression models with
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follow-up PCL-C as the dependent variable. We first tested each indepen-
dent variable separately (ie, only the candidate variable and initial PCL-C
score in the model). Then, variables that were at least marginally signifi-
cantly associated with follow-up PCL-C in these models (P  .10) were
included in a multiple linear regression to estimate the independent asso-
ciations of initial survey predictors with follow-up PCL-C. An additional
model was estimated that included both the initial survey predictors and
follow-up correlates. For the psychosocial measures, change scores
(follow-up score minus initial score) were used rather than follow-up
scores, so that the effect of changes in these measures independent of initial
status could be evaluated. Data management and statistical analyses were
conducted by using SAS Version 9.2 (SAS Institute, Cary, NC).
RESULTS
Patients and Recruitment
Of the 886 initial study participants, 176 had died, four were
ineligible (because of change in diagnosis or dementia), and 24 of
the mailed surveys were returned as undeliverable at follow-up. Of
the 682 eligible individuals who were assumed to have received a
follow-up survey, 566 (83%) completed and returned their survey,
107 (16%) did not respond, and nine (1%) refused to participate
(Fig 1).
Table 1. Demographic, Clinical, Psychosocial, and Post-Traumatic Stress Characteristics at the Time of the Initial Survey, by Participant
Status in the Follow-Up Survey
Characteristic
Participants (n  566) Nonparticipants (n  144)a
P bNo. % Mean  SD No. % Mean  SD
Demographics
Female sex 294 51.9 78 54.2 .633
White race 494 87.3 108 75.0  .001
Income  $30,000 113 22.2 53 41.4  .001
College or postgraduate degree 242 43.6 50 35.7 .091
Married or living with a partner 452 80.4 96 68.1 .001
Age, years 62.4  12.4 56.7  15.6  .001
Clinical characteristics
Had an indolent type of lymphoma 270 50.3 76 55.9 .243
Was diagnosed at stage  I 339 68.1 72 62.3 .224
Had received chemotherapy 446 78.8 103 71.5 .063
Had undergone a transplantationc 87 15.4 15 10.4 .130
Had received biologic therapy 166 29.3 30 20.8 .042
Was currently receiving treatment 58 10.4 22 15.6 .083
Had active diseased 47 9.1 20 15.9 .027
Had a recurrence of disease 184 33.2 39 28.7 .317
Time since diagnosis, years 10.4  7.1 9.5  6.5 .156
Mean comorbidity scoree 5.2  4.5 5.8  5.5 .166
Had a second primary cancer 71 12.7 16 11.4 .673
Psychosocial characteristics
Social Supportf 83.4  16.0 80.7  17.1 .079
IOC Negative Impactg 2.2  0.7 2.3  0.9 .080
IOC Positive Impacth 3.5  0.8 3.5  0.8 .978
Post-traumatic stress
PCL-C total scorei 26.1  9.0 28.8  11.8 .013
Re-experiencing 6.6  2.6 7.6  4.0 .006
Avoidance/numbing 10.4  4.1 11.4  4.8 .031
Arousal 9.1  3.6 9.8  4.5 .075
PCL-C total score  44j 28 5.0 16 11.6 .004
PCL-C symptomsk
None symptoms 351 62.8 81 58.7 .163
One 132 23.6 28 20.3
Two 43 7.7 15 10.9
Three 33 5.9 14 10.1
Abbreviations: IOC, Impact of Cancer Version 2 (IOCv2) survey; PCL-C, Post-Traumatic Stress Disorder (PTSD) Checklist, Civilian Version.
aAssumed living; of the 886 initial survey participants, 176 were confirmed to be deceased at follow-up.
bP value for comparison of participants and nonparticipants based on 2 for percentages and t test for means.
cBone marrow or stem-cell transplantation.
dWas not in remission or cured of non-Hodgkin’s lymphoma.
eSelf-Administered Comorbidity Questionnaire score; possible range, 0-42.
fMedical Outcomes Study Social Support Survey total score; possible range, 0-100; higher scores indicate more support.
gImpact of Cancer-Negative Impact Summary score; possible range, 1-5; higher scores indicate greater negative impacts.
hImpact of Cancer-Positive Impact Summary score; possible range, 1-5; higher scores indicate greater positive impacts.
iPCL-C continuous score; possible range, 17-85; higher scores indicate more symptoms (lower quality of life).
jPCL-C continuous score that is equal to or exceeds 44 is indicative of PTSD.18
kPCL-C symptom score; symptomatology is indicated by score  3 in one or more re-experiencing items, three or more avoidance items, or two or more arousal
items; more symptoms indicate lower quality of life; three symptoms are indicative of PTSD.
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Initial demographic, clinical, and psychosocial characteristics
and PTSD symptoms of the 566 individuals who participated in the
follow-up study and the 144 nonresponders are provided in Table 1.
The mean and median time since diagnosis for all participants was
10.4 and 8.0 years, respectively; the median time since diagnosis for the
subset that reported a recurrence was 8.8 years. Compared with dece-
dents (not shown in Table 1), follow-up study participants were more
likely to report the following characteristics on the initial survey:
income  $30,000, college degree, married or living with a partner,
younger age, aggressive lymphoma, no current treatment, no active
disease, lower comorbidity, lower IOC Negative Impact Summary
score, lower PCL-C score, and fewer PTSD symptoms (all P  .05). In
addition, follow-up study participants compared with nonresponders
were more likely to report white race, income  $30,000, married or
living with a partner, older age, received biologic therapy, no active
disease, and lower PCL-C scores (all P  .05). At follow-up, 41 (7.3%)
of 557 had a PCL-C score  44, which is indicative of PTSD,20 whereas
28 (5.0%) of 557 scored  44 at the time of the initial survey. The most
common PCL-C problems endorsed by participants as moderately to
extremely bothersome were sleep and concentration difficulties and
loss of interest in activities (Table 2).
PTSD Symptoms Over Time in Long-Term
NHL Survivors
The follow-up survey was completed an average of 4.8 years after
initial survey completion (range, 4.3 to 5.4 years). Total and subscale
scores for the comparison of the initial survey and the follow-up
PCL-C are listed in Table 3. Paired t tests found no significant change
in mean scores reported by the 557 participants who completed the
PCL-C at initial and follow-up surveys. However, the avoidance/
numbing subscale had the largest mean change or increase in symp-
toms of 0.2 (standard deviation, 3.6; P  .15).
Table 4 provides a cross tabulation of PTSD symptoms at the
time of the initial survey and follow-up. Among the 557 participants
who completed the PCL-C at both times, 281 (50.4%) did not report
symptoms at either time point, 68 (12.2%) reported a resolution of
symptoms, 23 (4.1%) reported improvement but persistent symp-
toms, 79 (14.2%) reported stable and persistent symptoms, and 106
(19.0%) reported a worsening of symptoms. In addition, 73 (13.1%)
reported a 5- to less than 10-point increase in PCL-C scores, which
represents reliable change (ie, worsening not due to chance). In addi-
tion, 39 (7.0%) reported at least a 10-point increase, considered to be
a clinically significant worsening of symptoms. Conversely, 88
(15.8%) reported at least a 5-point decrease in PCL-C scores (ie,
improvement of symptoms).21
Predictors and Correlates of PTSD Symptoms in
Long-Term NHL Survivors
The results of linear regression models are provided in Table 5,
the first set of models adjusting only for initial PCL-C score, the second
model adjusting for initial PCL-C score and significant predictors
(initial survey responses), and the third model adjusting for initial
PCL-C score, significant predictors, and significant correlates
(follow-up survey responses). For the models with adjustment for
initial PCL-C only (Column 1), the initial survey predictors of having
PTSD symptoms at follow-up were income less than $30,000
(P  .001), having an aggressive lymphoma (P  .025), stage  II at
diagnosis (P  .007), having had chemotherapy (P  .027), and IOC
Negative Impact Summary (P  .001) and IOC Positive Impact Sum-
mary (P  .006) scores. A recurrence in the last 5 years (P  .011),
higher follow-up comorbidity score (P  .003), and increase in IOC
Negative Impact Summary score (P  .001) were associated with
higher follow-up PCL-C. For the multiple linear regression model
with adjustment for initial PCL-C and other initial survey measures
(Column 2), the significant independent predictors of having more
PTSD symptoms at follow-up were income less than $30,000
(P  .001) and IOC Negative Impact Summary score (P  .001).
Regarding the multiple linear regression model with adjustment for
initial PCL-C, other initial measures, and changes in status between
the initial survey and follow-up (Column 3), the significant initial
survey predictors of greater PTSD symptoms at follow-up were in-
come less than $30,000 (P  .001), not currently receiving treatment
(P  .013), and IOC Negative Impact Summary (P  .001) and IOC
Positive Impact Summary (P  .030) scores. Increase in IOC Negative
Impact Summary score was also a significant correlate of follow-up
PCL-C (P  .001). For the models in Columns 2 and 3, R2 values were
0.55 and 0.65, respectively, indicating that the demographic, clinical,
and psychosocial variables accounted for a substantial amount of the
variance in follow-up PCL-C.
To shed further light on the findings related to negative and
positive impacts, Table 6 provides the IOC Subscale predictors and
correlates of follow-up PCL-C, with three models again controlling for
initial PCL-C and other factors. For the linear regression model with
adjustment for initial PCL-C only (Column 1), all of the IOC Negative
Table 2. PCL-C Items Endorsed by Participants As Moderately to Extremely
Bothersome at Follow-Up
Item No. PCL-C Item %
13 Trouble falling or staying asleep 38.1
15 Having difficulty concentrating 25.2
9 Loss of interest in activities that you used to enjoy 22.2
12 Feeling as if your future will somehow be cut short 18.3
16 Being “super-alert” or watchful or on guard 18.2
14 Feeling irritable or having angry outbursts 16.4
10 Feeling distant or cut off from other people 15.8
17 Feeling jumpy or easily startled 14.0
8 Trouble remembering important parts of the cancer and its
treatment
12.5
1 Repeated, disturbing memories, thoughts, or images of the
cancer and its treatment
12.4
6 Avoiding thinking about or talking about the cancer and its
treatment or avoiding having feelings related to it
10.6
11 Feeling emotionally numb or being unable to have loving
feelings for those close to you
10.5
4 Feeling very upset when something reminded you of the
cancer and its treatment
8.0
7 Avoiding activities or situations because they reminded you
of the cancer and its treatment
5.5
3 Suddenly acting or feeling as if the cancer and its treatment
were happening again (as if you were reliving it)
5.2
2 Repeated, disturbing dreams of the cancer and its
treatment
4.8
5 Having physical reactions (for example, heart pounding,
trouble breathing, or sweating) when something
reminded you of the cancer and its treatment
4.4
Abbreviation: PCL-C, Post-Traumatic Stress Disorder (PTSD) Checklist, Civil-
ian Version.
PCL-C symptom clusters: at least one re-experiencing item (1-5); at least
three avoidance/numbing items (6-12); and at least two arousal items (13-17).
Post-Traumatic Stress Symptoms in NHL Survivors Over Time
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and Positive Impact Subscale scores were significant predictors of
more PTSD symptoms at follow-up (all P  .05), except “Health
Awareness.” In addition, increases in IOC Negative Impact Subscale
scores were associated with greater PTSD symptoms at follow-up (all
P .001), but there were no associations for change in Positive Impact
Subscale scores. For the model with adjustment for initial PCL-C and
other initial measures (Column 2), a higher “Worry” score was the
only IOC Subscale associated with more PTSD symptoms at
follow-up (P  .019). Regarding the multiple linear regression model
adjusted for initial PCL-C and other initial and follow-up measures
(Column 3), IOC Negative Impact “Appearance Concerns,” “Life
Interferences,” and “Worry” scores were significant initial survey pre-
dictors of more follow-up PTSD symptoms (all P  .05). Further,
increases in IOC Negative Impact “Life Interferences” and “Worry”
scores were independently associated with higher PCL-C scores (both
P  .001). In addition, a decrease in the IOC Positive Impact “Positive
Self-Evaluation” score was an independent correlate of follow-up
PCL-C (P  .005).
DISCUSSION
In this follow-up study, the largest longitudinal study of PTSD symp-
tomatology among adult cancer survivors reported in the literature to
date, we found that although 51% of survivors did not have PTSD
symptoms at either time point, and 12% had PTSD symptoms that
resolved over 5 years, more than one third of the sample reported
persistent (18%) or worsening (19%) PTSD symptoms over a 5-year
period. These findings of persistent PTSD symptomatology among
NHL survivors are consistent with those found among disaster vic-
tims22,23 and victims of violence.24-26 Importantly, several character-
istics were identified that could help screen and target treatments for
those survivors who are at risk for prolonged PTSD symptoms and
inform opportunities to reduce the impact of potentially PTSD-
inducing cancer care scenarios.
Although our hypotheses were partially supported (eg, finding of
persisting and worsening of symptoms), we found that the explana-
tion for follow-up PTSD symptoms was not limited to recurrence
status. Specifically, individuals with an initial status of lower income,
aggressive lymphoma, stage  II at diagnosis, having had chemother-
apy, and higher IOC Negative and Positive Impact Summary scores
were more likely to have more PTSD symptoms 5 years later. Impor-
tantly, income and Negative Impacts were most influential in adjusted
analyses (ie, more strongly predictive of PTSD symptoms) than the
clinical aspects of the disease and treatment.
How might these findings be used? Two strong messages emerge:
(1) the upfront cancer treatment experience directly influences down-
stream patient experience and risk of PTSD, and (2) specific individ-
uals are at increased risk. Therefore, whole-person interventions
Table 3. Comparison of Initial and Follow-Up PCL-C Scores (n  557)
Outcome






Mean [] t PMean SD Mean SD Mean SD
PCL-C total score 26.1 9.0 26.4 9.6 0.3 7.4 0.4 to 0.9 0.79 .43
Re-experiencing 6.6 2.6 6.5 2.7 0.1 2.5 0.3 to 0.1 0.72 .47
Avoidance/numbing 10.4 4.1 10.6 4.3 0.2 3.6 0.1 to 0.5 1.44 .15
Arousal 9.1 3.6 9.2 3.9 0.1 3.2 0.1 to 0.4 0.77 .44
Abbreviations: PCL-C, Post-Traumatic Stress Disorder (PTSD) Checklist, Civilian Version; SD, standard deviation.
PCL-C continuous score; total score possible range, 17-85; re-experiencing score possible range, 5-25; avoidance/numbing score possible range, 7-35; arousal
score possible range, 5-25; higher scores indicate more symptoms (lower quality of life).
Table 4. Cross Tabulation of PCL-C Symptom Scores at Initial and Follow-Up Surveys (n  557)
Post-Traumatic Stress
Symptoms at Initial Survey
Post-Traumatic Stress Symptoms at Follow-Up Survey
0 1 2 3 Total
No. of Patients % No. of Patients % No. of Patients % No. of Patients % No. of Patients %
0 281 80.3 51¶ 14.6¶ 11¶ 3.1¶ 7¶ 2.0¶ 350 62.8
1 53† 40.2† 46§ 34.8§ 20¶ 15.2¶ 13¶ 9.8¶ 132 23.7
2 12† 28.6† 11‡ 26.2‡ 15§ 35.7§ 4¶ 9.5¶ 42 7.5
3 3† 9.1† 9‡ 27.3‡ 3‡ 9.1‡ 18§ 54.5§ 33 5.9
Total 349 62.7 117 21.0 49 8.8 42 7.5 557 100
Abbreviation: PCL-C, Post-Traumatic Stress Disorder (PTSD) Checklist, Civilian Version.
PTSD symptoms are re-experiencing, avoidance/numbing, and arousal; higher scores represent more symptoms (ie, lower quality of life); three symptoms are
indicative of PTSD.
†Resolved or no symptoms.
‡Improved but persistent symptoms.
§Stable and persistent symptoms.
¶Worsening symptoms.
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targeted at improving the experience of patients with NHL, including
mitigating PTSD, could seek to do either or both of the following: (1)
improve those elements of the treatment experience that lead to neg-
ative impressions (eg, reducing life interference by social work inter-
vention, improving a sense of body image by physical therapy,
relieving worry by cognitive behavioral therapy), and (2) recognize
that NHL survivors from poor socioeconomic circumstances are at
the highest risk and triage efficiently to social support services. In
addition, clinical care should include a formal assessment of symp-
toms that includes domains similar to those on the IOC. However,
Table 5. Predictors and Correlates of Post-Traumatic Stress: PCL-Ca
Characteristic
Column 1
Adjusted for Initial PCL-Cb
Column 2 Adjusted for Initial PCL-C
and Other Predictors (n  521)c
Column 3 Adjusted for Initial
PCL-C, Other Predictors, and
Correlates (n  519)
Coefficient  SE P Coefficient  SE P Coefficient  SE P
Initial PCL-Cd 0.73 0.03  .001 0.60 0.05  .001 0.51 0.04  .001
Initial survey demographic variables
Female sex 0.82 0.60 .169
White race 1.31 0.91 .145
Income  $30,000 3.34 0.73  .001 3.84 0.77  .001 3.06 0.67  .001
Less than college degree 0.28 0.61 .649
Not married 0.27 0.76 .718
Age at study enrollment 0.01 0.02 .556
Initial survey clinical variables
Had an indolent type of lymphoma 1.38 0.61 .025 0.75 0.65 .249 0.22 0.58 .707
Stage I at diagnosis 1.80 0.66 .007 1.00 0.71 .163 0.48 0.63 .443
Had received chemotherapy 1.62 0.73 .027 0.50 0.81 .540 0.33 0.71 .647
Had undergone a transplantatione 1.24 0.83 .136
Had received biologic treatment 0.42 0.66 .520
Was currently receiving treatment 1.91 0.97 .050 1.88 1.00 .059 2.20 0.88 .013
Had active diseasef 0.99 1.08 .357
Recurrence statusg
Had one or more recurrences 0.21 0.65 .740
Was never in remission 1.59 1.38 .250
Years since diagnosis 0.03 0.04 .456
Comorbidity scoreh 0.07 0.07 .299
Had a second primary cancer 0.57 0.90 .523
Initial survey psychosocial variables
Social Supporti 0.01 0.02 .987
IOC Negative Impactj 2.55 0.60  .001 2.71 0.61  .001 4.51 0.58  .001
IOC Positive Impactk 1.06 0.38 .006 0.42 0.40 .296 0.77 0.35 .030
Follow-up clinical correlates
Was currently receiving treatment 1.47 1.15 .202
Had active disease 1.66 1.07 .121
Recurrence status
Had a recurrence in last 5 years 1.92 0.76 .011 0.72 0.68 .294
Was never in remission 0.46 1.33 .732
Comorbidity score 0.33 0.11 .003 0.09 0.10 .389
Had treatment in last 5 years 1.04 0.68 .127
Had a new cancer in last 5 years 0.72 1.06 .496
Follow-up psychosocial correlates
Social Support 0.03 0.02 .120
 IOC Negative Impact 5.18 0.50  .001 6.05 0.51  .001
 IOC Positive Impact 0.09 0.51 .857
Model-adjusted R2l 0.47 0.55 0.65
Abbreviations: IOC, Impact of Cancer Version 2 (IOCv2) survey; PCL-C, Post-Traumatic Stress Disorder (PTSD) Checklist, Civilian Version.
aPCL-C continuous score; total score possible range, 17-85.
bBaseline PCL-C; number of patients ranges from 493 to 557.
cRegression models also adjusted for missing data (ie, income and stage dummy variables).
dBaseline PCL-C; R2 ranges from 0.46 to 0.56.
eBone marrow or stem-cell transplantation.
fWas not in remission or cured of non-Hodgkin’s lymphoma.
gNo recurrence v had at least one recurrence, never in remission.
hSelf-Administered Comorbidity Questionnaire score; possible range, 0-42.
iMedical Outcomes Study Social Support Survey total score; possible range, 0-100; higher scores indicate more support.
jIOC-Negative Impact Summary score; possible range, 1-5; higher scores indicate greater negative impacts.
kIOC-Positive Impact Summary score; possible range, 1-5; higher scores indicate greater positive impacts.
lColumn 1 represents initial PCL-C score R2 statistic.
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additional testing of the IOC in other samples is needed to support its
use earlier in the cancer trajectory.
Although there are no known psychosocial interventions devel-
oped specifically for NHL survivors, evidence-based offerings could be
tailored to meet the unique needs of this population. The alternating
symptom-free and symptom exacerbation characteristics of NHL
coupled with the difficulty in distinguishing between signs of aging
and long-term symptoms from treatment may exacerbate worry or
fear of recurrence in survivors. The Managing Uncertainty Day-to-
Day intervention27 is designed to help older breast cancer survivors
manage fears of recurrence and improve coping skills by delivering
cognitive strategies via audiotape. In addition, a supportive-expressive
group therapy intervention has been shown to significantly reduce
trauma symptoms and mood disturbance in women with advanced
breast cancer.28 Thus, treatments exist that might benefit PTSD out-
comes of NHL survivors, especially if they are targeted to those of
greatest presumed risk.
The findings in this study are especially beneficial, given the large
sample size, excellent response rate, use of standardized measures, and
longitudinal design. Although our study included only two survey
administrations, it is a starting point of depicting the experiences of
patients with cancer. Study limitations include the representation of a
predominantly married and white sample and potential nonresponse
bias. However, our racial profile closely mirrors that of the national
population of NHL survivors, thereby strengthening the generalizabil-
ity of our findings. There is also evidence that individuals who chose
not to participate at follow-up were not doing well at the initial survey;
therefore, the level of PTSD symptomatology may be underestimated.
Second, the 28-page survey lacked measures assessing other psycho-
logical problems and life stressors in an effort to minimize the burden
on respondents. Third, potential biases inherent in the use of self-
report measures were minimized by using standardized instruments.
And last, there is a potential overlap of PTSD symptoms with those
related to cancer and treatment. However, only a small proportion
(9.4%) of the sample reported active NHL or receiving treatment at
follow-up. Furthermore, follow-up disease and treatment status were
not predictive of PTSD symptoms in the linear regression analysis.
In conclusion, this article provides new information about the
trajectory of PTSD symptoms in long-term NHL survivors. The initial
cancer experience (and the need to improve it) becomes paramount in
improving downstream outcomes, such as PTSD symptomatology. In
addition, the identification of several patient characteristics related to
PTSD risk could inform the screening process early in the survivorship
trajectory. Furthermore, the strong predictive role of the IOC is con-
sistent with previous cross-sectional studies and suggests that negative
perceptions related to the cancer experience could be targeted in
Table 6. IOC Subscale As a Predictor and Correlate of Post-Traumatic Stress: PCL-C
Subscale Item
Column 1
Adjusted for Initial PCL-C†
Column 2
Adjusted for Initial PCL-C and
Other Predictors (n  512)‡
Column 3
Adjusted for Initial PCL-C, Other
Predictors, and Correlates (n  508)§
Coefficient,  SE P Coefficient,  SE P Coefficient,  SE P
IOC predictors
Negative Impact¶
Appearance Concerns 1.07 0.40 .008 0.77 0.42 .071 1.15 0.44 .010
Body Change 1.17 0.31  .001 0.53 0.36 .142 0.24 0.40 .544
Life Interferences 1.98 0.58  .001 0.44 0.70 .529 1.61 0.72 .027
Worry 0.85 0.38 .024 0.98 0.42 .019 1.88 0.41  .001
Positive impact
Altruism/Empathy 0.80 0.32 .012 0.25 0.44 .565 0.30 0.39 .432
Health Awareness 0.47 0.36 .193
Meaning of Cancer 0.67 0.28 .016 0.46 0.35 .191 0.53 0.31 .089
Positive Self-Evaluation 0.69 0.30 .023 0.36 0.45 .421 0.30 0.44 .498
IOC correlates
Change () in Negative
Impact
 Appearance Concerns 1.57 0.37  .001 0.60 0.44 .173
 Body Change 1.93 0.32  .001 0.79 0.41 .052
 Life Interferences 3.62 0.43  .001 2.80 0.55  .001
 Worry 2.97 0.36  .001 2.02 0.44  .001
 Positive Impact
 Altruism/Empathy 0.51 0.39 .195
 Health Awareness 0.44 0.34 .193
 Meaning of Cancer 0.30 0.33 .365
 Positive Self-Evaluation 0.70 0.36 .053 1.00 0.34 .005
Abbreviations: IOC, Impact of Cancer Version 2 (IOCv2) survey; PCL-C, Post-Traumatic Stress Disorder (PTSD) Checklist, Civilian Version.
PCL-C continuous score; total score possible range, 17-85.
†No. of patients ranges from 493 to 557.
‡Regression model adjusted for initial PCL-C demographic, clinical, and psychosocial predictors and missing data (ie, income and stage dummy variables).
§Regression model adjusted for initial PCL-C demographic, clinical, and psychosocial predictors; follow-up clinical and psychosocial correlates; and missing data
(ie, income and stage dummy variables).
¶IOC-Negative Impact Summary score; possible range, 1-5; higher scores indicate greater negative impacts.
IOC-Positive Impact Summary score; possible range, 1-5; higher scores indicate greater positive impacts.
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interventions as a means to minimize PTSD symptomatology. Future
work should focus on the identification of patients at risk by using
predictive models applied at the point of care and development of
low-cost interventions that are delivered to those exhibiting clinically
significant PTSD symptomatology during treatment to improve the
long-term patient experience.
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